# Safety and Efficacy of Albuterol Administered by the Halix™ Dry Powder Inhaler in Subjects With Asthma

> **NCT03643874** · PHASE2 · COMPLETED · sponsor: **Concentrx Pharmaceuticals, Inc.** · enrollment: 13 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Halix albuterol 90 mcg
- **DRUG:** albuterol HFA MDI 90 mcg

## Key facts

- **NCT ID:** NCT03643874
- **Lead sponsor:** Concentrx Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-30
- **Primary completion:** 2018-08-31
- **Final completion:** 2018-09-30
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2019-01-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03643874

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03643874, "Safety and Efficacy of Albuterol Administered by the Halix™ Dry Powder Inhaler in Subjects With Asthma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03643874. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*